Why Abzena?
Our focused approach.
Despite streamlined processes and advances in technology solutions, workflows can be slow to produce successes and carry risk. Developing a biologic, such as a targeted monoclonal antibody (mAb), and delivering it to the market where there is a patient in need requires years of research and discovery, development, clinical trials and scale up for commercialization.
Abzena’s scientific experts in cell line development are ready to help answer your questions and collaborate with you. Here you can find and learn from our expert CLD resources. If you have any questions or would like to speak with an expert please contact us.
Please tell us about yourself and your program. Our experts will be in touch soon.